Edition:
United Kingdom

Alder Biopharmaceuticals Inc (ALDR.OQ)

ALDR.OQ on NASDAQ Stock Exchange Global Market

11.50USD
12 Dec 2018
Change (% chg)

$0.00 (+0.00%)
Prev Close
$11.50
Open
$11.53
Day's High
$11.88
Day's Low
$11.32
Volume
277,388
Avg. Vol
214,017
52-wk High
$20.85
52-wk Low
$10.48

Latest Key Developments (Source: Significant Developments)

Alder Biopharmaceuticals Q2 Loss Per Share $1.04
Tuesday, 7 Aug 2018 

Aug 7 (Reuters) - Alder Biopharmaceuticals Inc ::ALDER BIOPHARMACEUTICALS® REPORTS SECOND QUARTER 2018 FINANCIAL AND OPERATING RESULTS.Q2 LOSS PER SHARE $1.04.Q2 EARNINGS PER SHARE VIEW $-1.05 -- THOMSON REUTERS I/B/E/S.BIOLOGICS LICENSE APPLICATION (BLA) SUBMISSION ON TRACK FOR Q1 2019.ALL MILESTONES REMAIN ON TRACK FOR ALDER'S PLANNED BLA SUBMISSION IN Q1 2019.  Full Article

Alder Announces $250 Million Committed Equity Financing
Monday, 8 Jan 2018 

Jan 8 (Reuters) - Alder Biopharmaceuticals Inc ::ALDER ANNOUNCES $250 MILLION COMMITTED EQUITY FINANCING.ALDER BIOPHARMACEUTICALS INC - INVESTORS TO PURCHASE UP TO $250 MILLION OF NON-VOTING CLASS A PREFERRED STOCK DURING 3-YEAR TERM OF AGREEMENT.ALDER BIOPHARMACEUTICALS INC - TO USE NET PROCEEDS TO FUND PAYMENTS UNDER ALDER'S EUROPEAN PATENT SETTLEMENT.ALDER BIOPHARMACEUTICALS INC - TO ALSO USE PROCEEDS FOR EPTINEZUMAB INFUSION COMMERCIALIZATION-READINESS ACTIVITIES.  Full Article

Alder Biopharmaceuticals Enters Into European Patent Settlement, Global License Agreement With Teva
Monday, 8 Jan 2018 

Jan 8 (Reuters) - Alder Biopharmaceuticals Inc ::ALDER BIOPHARMACEUTICALS® ENTERS INTO EUROPEAN PATENT SETTLEMENT AND GLOBAL LICENSE AGREEMENT WITH TEVA IN THE FIELD OF ANTI-CGRP-BASED THERAPY.ALDER BIOPHARMACEUTICALS INC - ‍ALDER HAS AGREED TO MAKE AN IMMEDIATE ONE-TIME PAYMENT OF $25 MILLION TO TEVA​.ALDER BIOPHARMACEUTICALS INC - UNDER TERMS OF AGREEMENT, ALDER HAS AGREED TO WITHDRAW ITS APPEAL BEFORE EUROPEAN PATENT OFFICE.ALDER BIOPHARMACEUTICALS - UNDER TERMS CO AGREED TO PAY $75 MILLION AT EACH OF TWO SALES-RELATED MILESTONES FOLLOWING COMMERCIAL LAUNCH OF EPTINEZUMAB.ALDER SAYS UNDER TERMS CO AGREED TO PROVIDE CERTAIN ROYALTY PAYMENTS ON NET SALES AT RATES FROM 5% TO 7% FOLLOWING COMMERCIAL LAUNCH OF EPTINEZUMAB.ALDER - UNDER TERMS CO AGREED TO MAKE SECOND ONE-TIME PAYMENT OF $25 MILLION UPON APPROVAL OF BLA FOR EPTINEZUMAB WITH U.S. FDA.  Full Article

Alder Says Eptinezumab Met Primary Endpoint In Pivotal Phase 3 Promise 2 Clinical Trial
Monday, 8 Jan 2018 

Jan 8 (Reuters) - Alder Biopharmaceuticals Inc ::ALDER ANNOUNCES EPTINEZUMAB SIGNIFICANTLY REDUCES MIGRAINE RISK MEETS PRIMARY AND ALL KEY SECONDARY ENDPOINTS IN PIVOTAL PROMISE 2 PHASE 3 TRIAL FOR CHRONIC MIGRAINE PREVENTION.ALDER BIOPHARMACEUTICALS INC - ANNOUNCED THAT EPTINEZUMAB, MET PRIMARY ENDPOINT IN ITS PIVOTAL PHASE 3 PROMISE 2 CLINICAL TRIAL.ALDER BIOPHARMACEUTICALS INC - ‍15% OF PATIENTS HAD NO MIGRAINES FOR A FULL THREE MONTHS​.ALDER BIOPHARMACEUTICALS INC - IN ADDITION, EPTINEZUMAB MET ALL KEY SECONDARY ENDPOINTS WITH VERY HIGH STATISTICAL SIGNIFICANCE.ALDER BIOPHARMACEUTICALS INC - ‍SAFETY AND TOLERABILITY WERE SIMILAR TO PREVIOUSLY REPORTED EPTINEZUMAB STUDIES​.ALDER BIOPHARMACEUTICALS INC - PLANS TO SUBMIT A BLA TO U.S. FDA FOR EPTINEZUMAB IN H2 OF 2018.  Full Article

Alder Biopharmaceuticals Q3 loss per share $0.92
Tuesday, 7 Nov 2017 

Nov 7 (Reuters) - Alder Biopharmaceuticals Inc :Alder biopharmaceuticals announces third quarter 2017 financial and operating results.Q3 loss per share $0.92.Q3 earnings per share view $-1.17 -- Thomson Reuters I/B/E/S.Alder Biopharmaceuticals Inc - ‍eptinezumab biologics license application (BLA) submission on track for 2h18​.Alder Biopharmaceuticals Inc - ‍promise 2 pivotal trial completed enrollment and top-line data on track for 1h18​.Alder-Sees available cash & cash equivalents, short-term investments to be sufficient for projected requirements through late 2018/early 2019​‍​.  Full Article

RPT-FOCUS-Amgen's new migraine drug hits insurance hurdles

July 26 Amgen Inc's push to get patients on its new $575 a month migraine drug before competition emerges in September is facing barriers from insurers.